• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 12, 2022 at 10:32: AM
via When Bristol Myers Squibb originally unveiled pivotal data for Breyanzi in second-line large B-cell lymphoma (LBCL) a year ago, a key weak point was a short follow-up time in the study. Now, the New York pharma is cranking up its CAR-T rivalry against Gilead Sciences with updated results.

article source
 

<



Similar threads

cafead
ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell...
Replies
0
Views
168
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Replies
0
Views
222
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Bristol Myers&#039; Breyanzi, Gilead&#039;s Yescarta lock horns in race to move CAR-T...
Replies
0
Views
275
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Celgene&#039;s last hurrah at ASH a defining moment for Bristol-Myers&#039; buyout
Replies
0
Views
192
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Bristol&#039;s 3rd-line Abecma data didn&#039;t make the trip to New Orleans. Is it...
Replies
0
Views
178
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote